Quanterix Corp

QTRX

Laboratory Analytical Instruments

Mkt Cap

$629.8M

PE

-17.35

Debt

Cash

$47.89M

EV

FCF

-$33.71M

Market Cap

$629.8M

P/E Ratio

-17.35

Debt

Cash

$47.89M

EV

FCF

-$33.71M

Charts data: {"Earnings":[{"time":"2016-12-30","value":-27618000},{"time":"2017-12-30","value":-31188000},{"time":"2018-12-30","value":-31536000},{"time":"2019-12-30","value":-40796000},{"time":"2020-12-30","value":-31530000},{"time":"2021-12-30","value":-57688000},{"time":"2022-12-30","value":-96700000},{"time":"2023-12-30","value":-32334000}],"Sales":[{"time":"2016-12-30","value":17585000},{"time":"2017-12-30","value":22874000},{"time":"2018-12-30","value":37632000},{"time":"2019-12-30","value":56734000},{"time":"2020-12-30","value":86377000},{"time":"2021-12-30","value":110556000},{"time":"2022-12-30","value":105522000},{"time":"2023-12-30","value":122368000}],"Net Margins":[{"time":"2016-12-30","value":-1.5705430764856412},{"time":"2017-12-30","value":-1.3634694412870507},{"time":"2018-12-30","value":-0.8380102040816326},{"time":"2019-12-30","value":-0.7190749814925794},{"time":"2020-12-30","value":-0.3650277272885143},{"time":"2021-12-30","value":-0.521798907341076},{"time":"2022-12-30","value":-0.9163965808077936},{"time":"2023-12-30","value":-0.2642357479079498}],"Assets":[{"time":"2017-12-30","value":91779000},{"time":"2018-12-30","value":67611000},{"time":"2019-12-30","value":169951000},{"time":"2020-12-30","value":271045000},{"time":"2021-12-30","value":501527000},{"time":"2022-12-30","value":434199000},{"time":"2023-12-30","value":425011000}],"Stockholders Equity":[{"time":"2016-12-30","value":-115109000},{"time":"2017-12-30","value":65866000},{"time":"2018-12-30","value":41065000},{"time":"2019-12-30","value":128658000},{"time":"2020-12-30","value":206125000},{"time":"2021-12-30","value":440952000},{"time":"2022-12-30","value":358940000},{"time":"2023-12-30","value":346927000}],"ROE":[{"time":"2016-12-30","value":0.23992911066901806},{"time":"2017-12-30","value":-0.4735068168706161},{"time":"2018-12-30","value":-0.7679532448557166},{"time":"2019-12-30","value":-0.3170887158202366},{"time":"2020-12-30","value":-0.15296543359611886},{"time":"2021-12-30","value":-0.13082603095121464},{"time":"2022-12-30","value":-0.26940435727419626},{"time":"2023-12-30","value":-0.09320116335713277}],"ROA":[{"time":"2017-12-30","value":-0.2833436842850761},{"time":"2018-12-30","value":-0.4660632145656772},{"time":"2019-12-30","value":-0.2411459773699478},{"time":"2020-12-30","value":-0.11652677599660573},{"time":"2021-12-30","value":-0.1150964953033436},{"time":"2022-12-30","value":-0.22255924126955612},{"time":"2023-12-30","value":-0.0743863100013882}]}

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. The company also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

Sector

10-Q
9/30/23
10-Q
6/30/23
10-Q
3/31/23
10-K
12/31/22
10-Q
9/30/22
10-Q
6/30/22
10-Q
3/31/22
10-K
12/31/21
10-Q
9/30/21
10-Q
6/30/21
10-Q
3/31/21
10-K
12/31/20
10-Q
9/30/20
10-Q
6/30/20
10-Q
3/31/20
10-K
12/31/19
10-Q
9/30/19
10-Q
6/30/19
10-Q
3/31/19
10-K
12/31/18
10-Q
9/30/18
10-Q
6/30/18
10-Q
3/31/18
10-K
12/31/17

Chart P/E ratio

In the chart Earnings are multiplied by this value.

Earnings Growth -

Earnings Stability -

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

The Net Margin is too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Over time the ROA has been increasing indicating a higher marginal ROA with respect to the calculated one, giving a good sign for continued growth.

Years	12-2016	12-2017	12-2018	12-2019	12-2020	12-2021	12-2022	12-2023	TTM
Net Margin	-160%	-140%	-84%	-72%	-37%	-52%	-92%	-26%	-29%
ROA	-	-28%	-47%	-24%	-12%	-12%	-22%	-7.4%	-8.6%
ROE	24%	-47%	-77%	-32%	-15%	-13%	-27%	-9.3%	-11%

What is the average Net Margin?

The average Net Margin over the past 5 years is -60.41%.

What is the trend of Net Margin?

The trend of Net Margin over the past 5 years is +6.06%.

What is the average Return on Assets (ROA)?

The average ROA over the past 5 years is -20.6%.

What is the trend of Return on Assets (ROA)?

The trend of ROA over the past 5 years is +5.76%.

What is the average Return on Equity (ROE)?

The average ROE over the past 5 years is -28.86%.

What is the trend of Return on Equity (ROE)?

The trend of ROE over the past 5 years is +10.11%.

Safety & Stabiliy

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Data are missing

Years	12-2016	12-2017	12-2018	12-2019	12-2020	12-2021	12-2022	12-2023	TTM
Debt FCF	-	-0.40	-0.26	-0.21	-0.56	-	-	-	-
Debt Equity	-	0.14	0.19	0.06	0.07	-	-	-	-
MIN
Graham Stability	-	-	-	-	-	-	-	-	-

What is the Debt/FCF?

The Debt/FCF trailing twelve month is -.

What is the trend of Debt/FCF?

The trend of Debt/FCF over the past 5 years is -0.15.

What is the Graham’s Stability?

Graham’s Stability measure stands at -.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Data are missing

Years	12-2016	12-2018	12-2020	12-2022	Trend
Revenue	32%	27%	12%	16%	-7.3%
Net Income	-	-	-	-	-
Stockholders Equity	-	53%	19%	-3.3%	-13%
FCF	-	-	-	-	-

What is the 5 year Revenue CAGR?

The Revenue CAGR over the past 5 years is +26.6%.

What is the trend of Revenue growth?

The trend of Revenue growth rate over the past 5 years is -7.26%.

What is the 5 year Earnings CAGR?

The Earnings CAGR over the past 5 years is +0.5%.

What is the trend of Earnings growth?

The trend of Earnings growth rate over the past 5 years is -.

What is the 5 year Equity CAGR?

The Equity CAGR over the past 5 years is +53.23%.

What is the trend of Equity growth?

The trend of Equity growth rate over the past 5 years is -13.44%.

What is the 5 year FCF CAGR?

The FCF CAGR over the past 5 years is -5.58%.

What is the trend of FCF growth?

The trend of FCF growth rate over the past 5 years is -.